Case Report: Cetuximab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy

F1000Res. 2019 Jun 21:8:933. doi: 10.12688/f1000research.19149.2. eCollection 2019.

Abstract

We present the case of a 60-year-old man with unresectable cutaneous squamous cell carcinoma (cSCC) of the sternal area, which was not amenable to radiation therapy. The treatment history of this patient is remarkable as the disease had progressed through all lines of conventional therapy established in the literature. We decided to initiate treatment with epidermal growth factor receptor (EGFR) inhibitor cetuximab and we reassessed the patient after 12 weeks with a whole-body CT scan, documenting stability in the size and radiologic features of the disease. Cetuximab, like all current treatments for advanced cSCC, is administered off-label and proved effective in preventing further progression of disease in our patient.

Keywords: EGFR; cetuximab; cutaneous squamous cell carcinoma; non-melanoma skin cancer.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological* / therapeutic use
  • Carcinoma, Squamous Cell* / drug therapy
  • Cetuximab* / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Skin Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents, Immunological
  • Cetuximab

Grants and funding

Associazione Romana Ricerca Dermatologica covered the publication fees of this article as support to the authors.